about
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyX-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patternsProspective validation of the WHO proposals for the classification of myelodysplastic syndromesAddition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling.The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.[Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH].Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS.Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced diseasePrognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.The 5q- syndrome.Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesMorphology, cytogenetics and classification of MDS.CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).
P50
Q24563021-C2ACFE03-E14B-4E43-A358-671B8B7AA80FQ28242937-1A095898-3CBB-4DFC-84AB-82419F481393Q28277174-4EAAFDB4-0951-459C-B366-42A849D7376AQ30315977-704BE9BB-9E81-484C-A9D0-6D5624599443Q30883788-4171FA24-9262-4E0A-BE01-C713EF919CA6Q33214270-47268DD7-2A89-4F27-8E30-AA88ED4C116EQ33327379-B057EC22-305F-4632-A0A9-2311112B220FQ33379562-DC481A6F-F1C1-4EEA-AE2B-22BA3754CE4EQ33389683-20F9F871-7C60-4ECE-AA18-E2881BD7B25BQ33401083-44649E00-CF24-48C5-B697-D56D5423B41BQ33402942-47C8DFB9-96BE-443D-834D-63ACC0088989Q33403903-33C24631-80C0-4E83-8CA6-C7ABEA031641Q33404153-623F3C53-CB91-4B37-970E-6F77631D01E8Q33409611-D91DB367-F5F7-40F4-A7A5-7223C2296A5CQ33414453-AB4E8601-C30E-4CE3-ADAC-C4BCBF0BE588Q33416541-1D18EF38-DCD8-4D32-8211-6AFEE3191411Q33416547-7FA4EA9A-FA69-46EE-B6D5-2C25BAD5D438Q33428549-2FCFFB90-12CE-4963-B1A6-2C8E57DDB0EEQ33433485-BCD827F6-B405-426C-904A-45FC927E5258Q33695954-610167B6-62DD-426D-9A06-B39DB4FFA2F8Q33836662-1B542678-5FAF-493E-8024-0A6054F365C2Q34044905-A334F2E0-1B0E-4E0B-BB8B-32C06E97A5CBQ34516294-F3A71EAB-6CC7-430F-8D97-1ACE57525D45Q34928380-A615426C-2D3E-4462-A8F7-75387E139CACQ35230041-18CAA251-936A-4466-8632-9CF3666BAF26Q35611709-83BEE594-5E19-4E40-AC77-2DAA24B3113EQ36199373-80A8A0EA-83E4-4F62-9BD4-ADF7C7EEFB33Q36362180-9B91A11A-A0D0-4D73-9262-3D59973D158FQ36509631-C3352676-A10D-4960-86EB-FCBC8A9DED7BQ36579081-F27C7C02-70F8-4C44-86BD-D7B2B1110C36Q36715932-C16FE789-3BCE-4F1B-9A3D-EDE0CA3E2E92Q36737106-F27B572C-0079-4D9F-9F62-9815F8610F0AQ36920348-DC7EF57F-BFBB-4FA6-BA85-BA402BC8D596Q36920362-460158AB-35F0-4DB2-A42B-AE290E6E6E9CQ37088176-DBD643E5-8212-4329-96AF-64784BB74CD3Q37377901-271A84F2-F0F1-4C08-A343-F3873037E590Q37766785-24DEFB69-6534-4EE5-B228-262D1EF09D61Q38135713-9E176969-01FE-4E3E-8361-8BDB18DA1A32Q38186272-2894EBBD-58A0-4210-92B7-D843C87C3B0FQ38278197-34E5E723-EC65-4D6E-BDAE-A7FC7AB427D8
P50
name
Aristoteles A N Giagounidis
@en
Aristoteles A N Giagounidis
@nl
type
label
Aristoteles A N Giagounidis
@en
Aristoteles A N Giagounidis
@nl
prefLabel
Aristoteles A N Giagounidis
@en
Aristoteles A N Giagounidis
@nl